Previous 10 | Next 10 |
Experienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients de...
UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will participate in fireside chats at the following conferences in March: ...
Conference Call and Webcast Scheduled for Monday, March 2, 2020 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced ...
Aptose Biosciences (APS CN) initiated with Overweight rating at Piper Sandler. Shares up 2% premarket in U.S. (NASDAQ: APTO ). More news on: Aptose Biosciences Inc., BioDelivery Sciences International, Inc., BiomX Inc., Healthcare stocks news, Stocks on the move, , Read mor...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz Barrett, President and Chief Executive Officer, will present at the 38 th ...
Healthcare companies filing for mixed shelf offerings: More news on: Lannett Company, Inc., AVROBIO, Inc., UroGen Pharma Ltd., Healthcare stocks news, Read more ...
Potential for UGN 101 to be First Non-Surgical Therapy for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration (FDA) accepted for filing and granted priority review for its New Drug A...
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will participate in fireside chats at the following conferences in November: Stifel 2019 Healthcare Conference Tuesday...
Image source: The Motley Fool. UroGen Pharma Ltd. (NASDAQ: URGN) Q3 2019 Earnings Call Nov 12, 2019 , 8:30 a.m. ET Operator Continue reading
UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Conference Call November 12, 2019, 08:30 AM ET Company Participants Catherine Bechtold - Senior Director of IR Elizabeth Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - CFO Stephen Mullennix -...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...